Recent Insights into the Management of Behçet Syndrome

Yesim Ozguler, Ayse Ozdede, Gulen Hatemi Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology and Behçet Disease Research Center, Istanbul, TurkeyCorrespondence: Gulen HatemiIstanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, D...

Full description

Bibliographic Details
Main Authors: Ozguler Y, Ozdede A, Hatemi G
Format: Article
Language:English
Published: Dove Medical Press 2021-07-01
Series:Journal of Inflammation Research
Subjects:
Online Access:https://www.dovepress.com/recent-insights-into-the-management-of-behet-syndrome-peer-reviewed-fulltext-article-JIR
id doaj-634233baf6474120be18e3672eced3ae
record_format Article
spelling doaj-634233baf6474120be18e3672eced3ae2021-07-25T19:23:41ZengDove Medical PressJournal of Inflammation Research1178-70312021-07-01Volume 143429344167103Recent Insights into the Management of Behçet SyndromeOzguler YOzdede AHatemi GYesim Ozguler, Ayse Ozdede, Gulen Hatemi Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology and Behçet Disease Research Center, Istanbul, TurkeyCorrespondence: Gulen HatemiIstanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology and Behçet Disease Research Center, Istanbul, TurkeyTel +902124143000/ 21793Email gulenhatemi@yahoo.comAbstract: Behçet syndrome (BS) is a multisystem vasculitis with variable vessel involvement that shows significant heterogeneity among patients in terms of clinical manifestations and disease course. Treatment choice and response are both influenced by this heterogeneity. BS treatments’ main goals are to quickly suppress inflammatory exacerbations and prevent relapses in order to protect organ functions and provide good quality of life. Besides the long-term experience with steroids and traditional immunosuppressives, biologic drugs, especially TNF inhibitors, have gained increasing importance in the treatment of BS over the years. In this review, we aimed to give an overview of the studies with conventional and biological drugs with proven efficacy in the treatment of BS, as well as promising drugs and current management strategies according to clinical phenotypes.Keywords: Behçet syndrome, treatment, management, biologic agents, TNF inhibitorhttps://www.dovepress.com/recent-insights-into-the-management-of-behet-syndrome-peer-reviewed-fulltext-article-JIRbehçet syndrometreatmentmanagementbiologic agentstnf inhibitor
collection DOAJ
language English
format Article
sources DOAJ
author Ozguler Y
Ozdede A
Hatemi G
spellingShingle Ozguler Y
Ozdede A
Hatemi G
Recent Insights into the Management of Behçet Syndrome
Journal of Inflammation Research
behçet syndrome
treatment
management
biologic agents
tnf inhibitor
author_facet Ozguler Y
Ozdede A
Hatemi G
author_sort Ozguler Y
title Recent Insights into the Management of Behçet Syndrome
title_short Recent Insights into the Management of Behçet Syndrome
title_full Recent Insights into the Management of Behçet Syndrome
title_fullStr Recent Insights into the Management of Behçet Syndrome
title_full_unstemmed Recent Insights into the Management of Behçet Syndrome
title_sort recent insights into the management of behçet syndrome
publisher Dove Medical Press
series Journal of Inflammation Research
issn 1178-7031
publishDate 2021-07-01
description Yesim Ozguler, Ayse Ozdede, Gulen Hatemi Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology and Behçet Disease Research Center, Istanbul, TurkeyCorrespondence: Gulen HatemiIstanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology and Behçet Disease Research Center, Istanbul, TurkeyTel +902124143000/ 21793Email gulenhatemi@yahoo.comAbstract: Behçet syndrome (BS) is a multisystem vasculitis with variable vessel involvement that shows significant heterogeneity among patients in terms of clinical manifestations and disease course. Treatment choice and response are both influenced by this heterogeneity. BS treatments’ main goals are to quickly suppress inflammatory exacerbations and prevent relapses in order to protect organ functions and provide good quality of life. Besides the long-term experience with steroids and traditional immunosuppressives, biologic drugs, especially TNF inhibitors, have gained increasing importance in the treatment of BS over the years. In this review, we aimed to give an overview of the studies with conventional and biological drugs with proven efficacy in the treatment of BS, as well as promising drugs and current management strategies according to clinical phenotypes.Keywords: Behçet syndrome, treatment, management, biologic agents, TNF inhibitor
topic behçet syndrome
treatment
management
biologic agents
tnf inhibitor
url https://www.dovepress.com/recent-insights-into-the-management-of-behet-syndrome-peer-reviewed-fulltext-article-JIR
work_keys_str_mv AT ozgulery recentinsightsintothemanagementofbehccediletsyndrome
AT ozdedea recentinsightsintothemanagementofbehccediletsyndrome
AT hatemig recentinsightsintothemanagementofbehccediletsyndrome
_version_ 1721282529815691264